What's the point of a Ph3 for NEWS 2 endpoint with the same friggin patient size when the Ph2 ALREADY established statistically signficant efficacy and safety is already established from all other previous trials? It would be the definition of insane behavior: trying the same thing over and over again and expecting a different outcome. Is the EFF-DA insane?!?